Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The AI response correctly identifies that Section 5.1 describes semaglutide-induced thyroid C-cell tumors in rodents with unknown human relevance, correctly notes the MTC/MEN2 contraindication (Sections 4 and 5.1 cross-reference), and accurately captures the uncertainty regarding routine calcitonin/thyroid ultrasound monitoring. No contradictions were identified.
Category Scores
Accurate Statements
Semaglutide causes dose- and treatment-duration-dependent thyroid C-cell tumors in mice and rats, while human relevance is unknown (including whether it causes thyroid C-cell tumors such as MTC in humans).
Supported by OZEMPIC label Section 5.1: rodent thyroid C-cell tumors at clinically relevant exposures and “It is unknown whether OZEMPIC causes thyroid C-cell tumors, including MTC, in humans … human relevance … has not been determined.”
OZEMPIC is contraindicated in patients with a personal or family history of MTC or in patients with MEN2.
Supported by Section 4 contraindications and referenced in Section 5.1.
Routine monitoring of serum calcitonin or thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with OZEMPIC.
Supported by Section 5.1: “Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC …”
No contradictions are present for the cited elements.
Consistent with the provided label text for the specific claims evaluated.
Unsupported Statements
Contradictions
Important Omissions
The response did not explicitly mention that the label also recommends counseling patients about potential MTC risk and informing them of symptoms (e.g., neck mass, dysphagia, dyspnea, persistent hoarseness) and the follow-up evaluation if calcitonin is elevated or if thyroid nodules are found.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The evaluated statements accurately reflect the label’s warnings/contraindications and uncertainty regarding monitoring; omitted counseling/follow-up details are not part of the specific claim scope but are relevant to safe use.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Omitted label details related to counseling/symptom awareness and what to do if calcitonin is elevated or nodules are present.
Suggested Improvement
When discussing the thyroid C-cell tumor risk/monitoring uncertainty, also include the label’s counseling and symptom guidance and the label-recommended further evaluation if calcitonin is elevated or thyroid nodules are detected.